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Infectious bursal disease virus is an important poultry pathogen. It is dis-
tributed worldwide and causes significant economic losses. In this study, a system 
was adopted for the simultaneous monitoring of vaccine and virulent strains using 
reverse transcription polymerase chain reaction (RT-PCR). After the decay of ma-
ternal antibodies, chickens were vaccinated at the age of 37 days with a virus of 
intermediate virulence and challenged at 5, 10 and 14 days post vaccination (dpv). 
The challenge was done with IBDV strain CH/99. Sequencing of the hypervari-
able region of VP2 has shown that CH/99 belongs to the very virulent group of vi-
ruses. The vaccine virus could be found in the bursa of Fabricius, spleen, thymus 
and bone marrow until 24 dpv. The CH/99 challenge virus was found in the bursa 
and lymphoid organs when chickens were challenged at 5 and 10 dpv. When chal-
lenge was performed at 14 dpv, the pathogenic virus could not be found in the 
bursa and other lymphoid organs.  
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Infectious bursal disease virus (IBDV) causes disease in young chickens 
by depletion of lymphocytes in the bursa of Fabricius and other lymphoid or-
gans. IBDV belongs to the Birnaviridae family since the genome consists of 
double-stranded bisegmented RNA. The larger segment A encodes the viral 
polyprotein that is autocatalytically cleaved to produce viral proteins VP2, VP4 
and VP3. A small open reading frame (ORF) partially overlapping the larger 
ORF encodes the VP5 protein. Genome segment B encodes the RNA-dependent 
RNA polymerase protein designated VP1 (Mundt et al., 1995). Mutations in the 
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hypervariable domain of VP2 can affect virulence and dominantly determine the 
antigenic nature of the virus (Azad et al., 1987; Rudd et al., 2002). IBDVs be-
longing to serotype 1 are infectious for chickens and, based on their pathogenic-
ity, are further divided to attenuated, classic virulent and very virulent strains. On 
the American continent, antigenic variant viruses are present on poultry farms. 
These viruses do not cause an inflammatory reaction in the bursa during infec-
tion but severe atrophy of the bursa and immune suppression are observed. Sero-
type 2 viruses found in turkeys are not pathogenic for chickens or turkeys 
(Lasher and Shane, 1994). 
Vaccination and good farm management are the only way to cope with the 
disease caused by IBDV. Since the beginning of the 1990s the very virulent vi-
ruses (vvIBDV) appeared in most countries of the world and this has made vac-
cination efforts more difficult. Namely, the vvIBDV can break through the ma-
ternal antibodies and infect young chickens before the live vaccine viruses have 
time to produce active immunity (Lasher and Shane, 1994). It has been reported 
that the presence of maternal antibodies causes a delay in the induction of anti-
bodies by live attenuated vaccines and this creates an ‘open window’ for the in-
fection with vvIBDV to occur (Rautenschlein et al., 2005; Zorman-Rojs et al., 
2011). We postulated that on contaminated farms, pathogenic virus can co-exist 
with the vaccine strains, for a certain period of time, even if clinical disease does 
not develop. As such, the virus could contaminate poultry houses and subse-
quently be transmitted to healthy chickens. 
The purpose of this research was to establish a method for the simultane-
ous detection of vaccine and pathogenic vvIBDV in Serbia with specific primers 
used in RT-PCR assay. This shall provide an assay for the detection of both vi-
ruses during the course of an IBDV infection in the field. Moreover, we were in-
terested in finding out whether the pathogenic virus multiplies in the presence of 
a vaccine strain infection and for how long it could be detected in immunised 
chickens. 
 
Materials and methods 
Extraction of viral RNA and reverse transcription polymerase chain reaction 
(RT-PCR) 
Viral RNA was extracted using the QIAamp viral RNA mini kit (Qiagen, 
Hilden, Germany). The samples of RNA were stored at –80 °C until use. First 
the RT-PCR of the hypervariable region of VP2 in the CH/99 challenge strain 
was done. We used the primers that are recommended in the Sixth Edition of the 
Manual of Standards for Diagnostic Tests and Vaccines for Terrestrial Animals 
(OIE, 2008). The product length was 604 base pairs (bp). Specific primers de-
scribed by Kusk et al. (2005) were applied for IBDV detection in the challenge 
experiment. The sequences of the primers are given in Table 1. Briefly, the prim-
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ers Vv-fp775 and Vv-rp1028 were designed to amplify a DNA fragment encom-
passing Alanine at 222 to Isoleucine at 294 of a vvIBDV strain. Another set of 
primers F52/D78/fp776 and D78/rp955 was specific for D78 vaccine virus and 
was designed for amplification of a gene fragment coding from Proline at 222 to 
Threonine at 270. The SuperScript III Platinum Quantitative One step RT/PCR 
System (Invitrogen, Carlsbad, California, USA) in single tube reaction was used. 
The reaction volume was 25 µl. Reverse transcription was done using the follow-
ing conditions: denaturation 95 °C/2 min and reverse transcription 55 °C/30 min, 
enzyme inactivation 95 °C/5 min, cooling at 4 °C. The polymerase chain reaction 
was performed as follows: initialization 94 °C/2 min and 37 cycles of denatura-
tion 94 °C/15 s, annealing 62 °C/30 s, extension 72 °C/30 s, final elongation 
72 °C/5 min. 
The products were visualised in 2% agarose using gel electrophoresis (ul-
trapure agarose, Invitrogen, Carlsbad, California, USA) in TBE buffer with 
ethidium bromide. A 100-bp DNA marker was used (Fermentas, Lithuania). The 
length of amplicons was 143 bp for the vaccine virus, while the product size for 
the virulent virus was 215 bp. 
Table 1 
Description of oligonucleotide primers used for amplification and sequencing of IBDV RNA 
Primer Sequence (5’–3’) Locationa Polarityb 
Vv-fp775 AATTCTCATCACAGTACCAAG 775–795 + 
Vv-rp1028 GCTGGTTGGAATCACAAT 1011–1028 – 
F52/D78-fp776 ATTCTCATCACAGTACCAAC 776–795 + 
D78-rp955 GCCCTGGTGATTACCGT 939–955 – 
aNucleotide location numbered according to the F52/70 complete sequence (GenBank accession 
number D00869); bSense (+) or antisense (–) primers 
Sequencing of the PCR products 
The PCR products for the CH/99 virus were sequenced to determine 
whether the virulence markers for vvIBDV were present in this strain. The PCR 
product was purified using the QIAquick gel extraction kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. Quantification of DNA 
was done with the GeneRuler molecular standard (Fermentas, Lithuania). Se-
quencing was done according to the Sanger method with BigDye Terminator 
v3.1 kit (Applied Biosystems, USA). The alignment was done with the ClustalW 
programme. For the sequence comparison, the vvIBDV UK661 sequence was 
obtained from the GenBank (accession number X92760). 
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Viruses and preparation of challenge virus stock 
The vaccine strain D78 was used to immunise chickens in this experiment. 
The very virulent strain CH/99 was initially isolated from commercial pullets 
around 4 weeks of age that had previously been vaccinated on three occasions 
with a vaccine of intermediate virulence. The mortality in the flock was 20% 
(unpublished data). For this experiment, the CH/99 virus was used to challenge 6 
broilers and subsequently 22 layer chickens free of antibodies to IBDV. The 
chickens were challenged with 0.1 ml of the diluted virus into the eyes and nos-
trils. The mortality rate was 33% in broilers and 27% in layers. The chickens that 
survived were sacrificed at 4 days post infection (dpi) according to the provisions 
of Directive 86/609/EEC. Bursae were collected and homogenates were prepared 
in PBS at the ratio of 1:10. The supernatant from the bursa homogenates was 
stored at –80 °C until use. 
Experimental design 
Day-old layer chickens were divided into three experimental groups 
marked O1, O2 and O3 and two control groups designated K0 and K1. Group K0 
was neither vaccinated nor challenged and was used as a negative control. Group 
K1 was vaccinated but not challenged. Groups O1–O3 were vaccinated and chal-
lenged at different ages. In each group there were 30 chickens. The chickens 
were held in isolation rooms with feed and water ad libitum. At 35 days of age, 
blood samples were taken from 5 chickens per group. Antibodies were not found 
and subsequently the chickens were vaccinated and then challenged. At 37 days 
of age, Groups K1, O1, O2 and O3 were vaccinated with one dose of the com-
mercial vaccine of intermediate virulence (D78 vaccine strain) by the oral route. 
At 5, 10 and 14 days post vaccination (dpv) blood samples were taken from 
chickens in groups O1, O2 and O3, respectively, and the chickens were subse-
quently challenged with the highly pathogenic IBDV (strain CH/99). The chal-
lenge was done orally with the prepared bursa homogenate diluted 1:10 in PBS. 
At 3, 7 and 10 dpi 3 chickens per group were sacrificed and the bursa, thymus, 
spleen and bone marrow were collected for RT-PCR analysis. 
Serology 
Serology testing was done by the use of a commercial ELISA kit (IDEXX 
Laboratories, Maine, USA) according to the manufacturer’s instructions. The 
cut-off value was the titre of 396. 
 
Results 
The hypervariable region of the VP2 gene of virus CH/99 was sequenced. 
The sequence includes nucleotides corresponding to 657–676 and 1193–1212 bp, 
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coding for key amino acids essential for analysing the pathogenic nature of 
IBDV. The critical amino acids included Alanine (Ala) at 222, 284, Isoleucine 
(Ile) at 242, 256, 294, Glutamine (Gln) at 253 and Serine (Ser) at 299 (data not 
shown). The sequence alignments showed 99.07% nucleotide and 100% amino 
acid identity with the UK661 virus strain (Rudd et al., 2002), confirming that 
CH/99 belongs to the group of very virulent IBDVs. The sequence of CH/99 was 
submitted to the GenBank and was assigned the accession number KF439863. 
In vaccinated and challenged birds, mortality and morbidity were not ob-
served during the experiment. In the bursa and non-bursal organs of the control 
group (K0), neither the vaccine nor the pathogenic virus was detected using RT-
PCR. In Group K1, vaccine virus was detected in organs throughout the experi-
ment, i.e. at 5, 10 and 14 dpv (data not shown). The vaccine virus was also de-
tected in all bursa samples during the experiment in Groups O1, O2 and O3, and 
it could be detected in the spleen and the thymus. In the bone marrow it was ab-
sent in Group O3 (chickens infected at 14 dpv), except in one sample at 7 dpi. 
The virulent virus CH/99 was found in the bursa and other lymphoid organs in 
Groups O1 and O2 (5 and 10 dpv) throughout the experiment. If the infection 
was done at 14 dpv (Group O3), the RT-PCR for challenge virus was negative in 
the bursa, spleen, thymus and bone marrow (Fig. 1). 
The results of serology are presented in Fig. 2. At 35 days of age, antibody 
ELISA test was negative in all groups. At 5 dpv, IBDV antibodies were also not 
found in the chickens tested (Groups K1 and O1). Ten days post vaccination, low 
antibody titre was found in the vaccinated birds (Groups K1 and O2). As ex-
pected, at 14 dpv the antibody titre was increased, showing further development 
of humoral response to vaccination (Fig. 2). 
 
 
Discussion 
In this study, the CH/99 virus was sequenced to determine its genetic rela-
tionship to vvIBDV strains. Molecular data on the hypervariable domain of VP2 
for IBDV isolated in Southeastern Europe were reported by Zorman-Rojs et al. 
(2003). The sequences obtained in their research showed a high percentage of 
identity with the vvIBDV strain UK661 (Zorman-Rojs et al., 2003). A similar re-
sult was obtained with the CH/99 virus. Because village chickens are not vacci-
nated regularly, backyard chicken flocks present a reservoir for the virus in Ser-
bia. Multi-age farming in broiler and some layer farms is occasionally practised 
in Serbia. Since older birds increase the risk of vvIBDV transmission to younger 
birds, we wanted to check whether it is possible to detect very virulent virus in 
vaccinated chickens. We attempted to introduce a system for the selective detec-
tion of both viruses (i.e. D78 vaccine and very virulent viruses) with the RT-PCR 
method. The vaccine virus was found in the bursa as long as 14 dpv. The results 
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Detection of D78 vaccine strain after challenge at 5 days post 
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Detection of D78 vaccine strain after challenge at 10 dpv
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Detection of D78 vaccine strain after challenge at 14 dpv
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Fig. 1. Detection of the RT-PCR products for vaccine virus (D78) and vvIBDV (CH/99) during the 
experiment 
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Detection of challenge strain CH/99 at 5 dpv
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Detection of challenge strain CH/99 at 10 dpv
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Detection of challenge strain CH/99 at 14 dpv
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Fig. 1 (Continued) 
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Fig. 2. ELISA antibody titres: 1 – at 35 days of age, ELISA titres before vaccination at 37 days of 
age; 2 – at 42 days of age, on the day of challenge, Group O1; 3 – at 47 days of age, on the day of 
challenge, Group O2; 4 – at 51 days of age, on the day of challenge, Group O3 
obtained are similar to those found in the experiments of Rautenschlein et al. 
(2005) who detected vaccine virus of intermediate virulence at 14 dpv by immu-
nohistochemical staining, while the intermediate plus vaccine strain was detectable 
as long as 21 dpv. In this experiment the vaccine virus was also found in the 
spleen, thymus and bone marrow. It is interesting to note that, in one bone marrow 
sample, the vaccine strain of IBDV was present even at 21 dpv. Kabell et al. 
(2005) detected vaccine virus in the bursa only. Combining the RT-PCR test and 
ELISA, Barlič-Maganja et al. (2002) succeeded in detecting the vaccine virus in 
the spleen, thymus and caecal tonsils for prolonged periods of time. In this respect, 
our results are in good correlation with theirs. Tanimura et al. (1995) found the J1 
strain (mild virus) in caecal tonsils and thymus at 7 dpi using immunohistochemi-
cal staining. Tsukamoto et al. (1995) used an antigen capture ELISA test to detect 
mild and very virulent viruses in the lymphoid organs of infected SPF chickens. 
The mild strains could not be found in the thymus, spleen and bone marrow after 3 
dpi. Differences in the results of detection of the vaccine virus in various experi-
ments are possibly due to the age of chickens at the time of infection, the breed and 
the various laboratory methods used in the studies. It was previously discovered 
that very virulent viruses multiply to higher titres in non-bursal organs, compared 
to moderately virulent strains (Tanimura et al., 1995). The very virulent strain 
Ehime/91 was found at 7 dpi only in the bursa and spleen in the experiment of 
Tsukamoto et al. (1995). In the experiment presented here the challenge virus was 
detected in almost all bursae and non-bursal organs when infection took place at 5 
dpv (Group O1). If infection was done at 10 dpv (Group O2), the CH/99 virus was 
present in all bursae at 3 dpi and could be detected in one bird each from spleen, 
bone marrow or thymus at different time points after challenge. The CH/99 virus 
was completely absent when challenge was done at 14 dpv. It was previously pos-
tulated that the vaccine and virulent viruses diminish due to clearance of the virus 
by the antibodies (Iván et al., 2005). This assumption could explain the disappear-
ance of the vvIBDV in some lymphoid organs in birds infected at 10 dpv in this 
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experiment (Fig. 1). The long presence of the vaccine virus is perhaps due to other 
mechanisms. It could be postulated that if the vaccine virus infects bursal cells be-
fore the virulent strain, it develops an advantage, most likely enhancing specific 
cellular/immunological processes and functions. In the research of Jackwood 
(2011), chickens with maternal antibodies were infected with vvIBDV at different 
time points. It was concluded that maternally derived antibodies have strong pro-
tective effect, but did not prevent replication of the vvIBDV even though at 2 
weeks of age the antibody titre was high. The author also reported that variant vi-
ruses prevented replication of vvIBDV if inoculated into the chickens 10 days be-
fore vvIBDV and 48 h before vvIBDV. When vvIBDV was given simultaneously 
with the variants, the clinical signs characteristic of very virulent viruses occurred 
and the bursal lesions resembled those typical of vvIBDV infection. High levels of 
maternal antibodies but also the persistent infection with variant viruses may ex-
plain the relative absence of vvIBDV in the USA. In our experiment, antibody ti-
tres induced with the vaccine virus well correlated with detection of the challenge 
virus in the bursa. When the challenge was performed in face of high antibody 
level at 14 dpv, both the clinical signs and the replication of vvIBDV were pre-
vented. When antibodies were absent at 5 dpv, the vvIBDV was present in the 
bursa and other lymphoid organs, but the disease did not develop, in the same way 
as observed in the experiments of Jackwood (2011). The humoral immune re-
sponse has a major role in protection against IBDV. However, there is evidence 
that cell-mediated immunity also plays an important part in the protection against 
early virus infection. This is supported by finding an influx of T cells in the bursa 
(Tanimura and Sharma, 1997). It was also shown that T cells become activated 
during IBDV infection (Kim et al., 2000), that cytokines IL-2 and IFNγ are re-
leased during the early stage of the infection (Rautenschlein et al., 2002) and that 
in bursectomised chickens T cells are responsible for virus clearance (Yeh et al., 
2002). Since at 5 dpv clinical protection against IBDV occurs in infected chickens, 
it could be postulated that a cell-mediated immune response may have prevented 
strong replication of the vvIBDV strain CH/99. 
From the present research we conclude that in vaccinated flocks receiving 
an intermediate vaccine the very virulent virus can produce subclinical infection 
for a limited period only. The possibility of spreading the very virulent virus 
among vaccinated flocks presents an additional risk for farmers that practise 
multi-age farm management. Careful monitoring of IBDV epidemiology is im-
portant and needs to be backed up with sensitive laboratory diagnostic methods. 
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